Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05998135 · ClinicalTrials.gov registry record · Phase 2

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

A Phase 2 study of Platinum-Resistant Ovarian Carcinoma and Ovarian High Grade Serous Adenocarcinoma, sponsored by Emory University.

Recruiting
Registry status
Phase 2
Development phase
28
Enrollment target
1
Study location

NCT05998135 is a Phase 2 study of Platinum-Resistant Ovarian Carcinoma and Ovarian High Grade Serous Adenocarcinoma that is actively recruiting participants, run by Emory University. The registered enrollment target is 28 participants, below the 43-participant average among 13 other Platinum-Resistant Ovarian Carcinoma trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05998135, a Phase 2 study of Platinum-Resistant Ovarian Carcinoma and Ovarian High Grade Serous Adenocarcinoma, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

Conditions Studied

Platinum-Resistant Ovarian Carcinoma Ovarian High Grade Serous Adenocarcinoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy
  • DRUG Atovaquone
  • PROCEDURE Paracentesis

Study Locations (1)

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2023-11-09
Est. Completion 2027-06-30
Phase Phase 2

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05998135

The ClinicalTrials.gov registry entry for NCT05998135 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 43-participant average among 13 other Platinum-Resistant Ovarian Carcinoma trials with a reported enrollment target (35% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Platinum-Resistant Ovarian Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.

NCT05998135 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT05998135 about?

NCT05998135 is a clinical study titled "Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer". This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the gr...

What is the current status of trial NCT05998135?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2023-11-09. Estimated completion is 2027-06-30.

What conditions does trial NCT05998135 study?

This clinical trial studies the following conditions: Platinum-Resistant Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma.

What interventions are being tested in trial NCT05998135?

The interventions under investigation include: Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Atovaquone (DRUG), Paracentesis (PROCEDURE).

Who is sponsoring clinical trial NCT05998135?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05998135 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Platinum-Resistant Ovarian Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Platinum-Resistant Ovarian Carcinoma

All registered trials for this condition

Ovarian High Grade Serous Adenocarcinoma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.